Ondansetron Eg

Ondansetron, the active ingredient in Ondansetron Eg, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective serotonin 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: Helps reduce the frequency and severity of nausea and vomiting caused by cytotoxic chemotherapy. - Radiation‑induced nausea and vomiting: Decreases nausea and vomiting associated with therapeutic radiation. - Post‑operative nausea and vomiting: Reduces the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related nausea and vomiting: Provides symptomatic relief for nausea and vomiting during pregnancy, when prescribed. - Hyper‑cortical     

Common